ANDASUBLINGUALTABLET
Approved
Jan 2016
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
buprenorphine, a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.
Indications (1)
Clinical Trials (5)
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
Started Mar 2026
60 enrolled
Opioid Use Disorder
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Started Dec 2025
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Started Dec 2025
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
Started Jan 2025
60 enrolled
Opioid Use Disorder
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Started Mar 2023
132 enrolled
Opioid Use Disorder